Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis

BACKGROUND: In recent years, new therapeutic combinations based on immunotherapy provided significant benefits as a first-line treatment for patients with advanced renal cell carcinoma (mRCC). OBJECTIVE: This work aims to address the lack of head-to-head comparisons and the uncertainty of the benefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cattrini, Carlo, Messina, Carlo, Airoldi, Chiara, Buti, Sebastiano, Roviello, Giandomenico, Mennitto, Alessia, Caffo, Orazio, Gennari, Alessandra, Bersanelli, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558789/
https://www.ncbi.nlm.nih.gov/pubmed/34733356
http://dx.doi.org/10.1177/17562872211053189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558789/
https://www.ncbi.nlm.nih.gov/pubmed/34733356
http://dx.doi.org/10.1177/17562872211053189

Ejemplares similares